Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Taysha Gene Therapies (TSHA) Shares Outstanding (Weighted Average) (2022 - 2025)

Historic Shares Outstanding (Weighted Average) for Taysha Gene Therapies (TSHA) over the last 4 years, with Q3 2025 value amounting to $353.3 million.

  • Taysha Gene Therapies' Shares Outstanding (Weighted Average) rose 3191.85% to $353.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $353.3 million, marking a year-over-year increase of 3191.85%. This contributed to the annual value of $250.1 million for FY2024, which is 11540.75% up from last year.
  • Taysha Gene Therapies' Shares Outstanding (Weighted Average) amounted to $353.3 million in Q3 2025, which was up 3191.85% from $298.0 million recorded in Q2 2025.
  • Taysha Gene Therapies' Shares Outstanding (Weighted Average)'s 5-year high stood at $353.3 million during Q3 2025, with a 5-year trough of $38.2 million in Q1 2022.
  • Over the past 4 years, Taysha Gene Therapies' median Shares Outstanding (Weighted Average) value was $125.7 million (recorded in 2023), while the average stood at $162.3 million.
  • In the last 5 years, Taysha Gene Therapies' Shares Outstanding (Weighted Average) surged by 26554.86% in 2024 and then soared by 1645.71% in 2025.
  • Quarter analysis of 4 years shows Taysha Gene Therapies' Shares Outstanding (Weighted Average) stood at $44.0 million in 2022, then surged by 164.2% to $116.1 million in 2023, then surged by 115.41% to $250.1 million in 2024, then soared by 41.25% to $353.3 million in 2025.
  • Its last three reported values are $353.3 million in Q3 2025, $298.0 million for Q2 2025, and $269.3 million during Q1 2025.